Operator

Good afternoon. This is the Chorus Call conference operator. Welcome, and thank you for joining the DiaSorin First Quarter 2026 Results Conference Call. [Operator Instructions] At this time, I would like to turn the conference over to Mr. Carlo Rosa, CEO of DiaSorin. Please go ahead, sir.

Carlo Rosa
CEO, GM & Executive Director

Thank you, operator. Ladies and gentlemen, good afternoon, and welcome to the Q1 conference call. As usual, I will give some color to the financial results, and then I will let our CFO, Alberto Donati, to take you through the numbers. I'm going to make my comments at constant exchange rate.

In quarter 1, 2026, as anticipated during our full year results call, the quarter registered a slightly negative performance, minus 3% and mainly as a result of the following factors. First one, as reported by all our competitors, the softness of the flu season with declining volume by roughly 25%.

And this clearly has affected the performance of our molecular diagnostic platforms since a good chunk of business today, especially in multiplexing is related to products in the respiratory area. As far as LTG, if we did comment before a tough comparison with the same period of last year. But in this case, we expect that by -- in the second half of the year, the trend will revert.